141 related articles for article (PubMed ID: 28573394)
1. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.
But A; De Bruin ML; Bazelier MT; Hjellvik V; Andersen M; Auvinen A; Starup-Linde J; Schmidt MK; Furu K; de Vries F; Karlstad Ø; Ekström N; Haukka J
Diabetologia; 2017 Sep; 60(9):1691-1703. PubMed ID: 28573394
[TBL] [Abstract][Full Text] [Related]
2. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
3. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
4. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
7. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
8. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
Jonasson JM; Ljung R; Talbäck M; Haglund B; Gudbjörnsdòttir S; Steineck G
Diabetologia; 2009 Sep; 52(9):1745-54. PubMed ID: 19588120
[TBL] [Abstract][Full Text] [Related]
11. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
12. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
[TBL] [Abstract][Full Text] [Related]
14. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes.
Makino H; Tanaka A; Hosoda H; Koezuka R; Tochiya M; Ohata Y; Tamanaha T; Miyamoto Y; Kangawa K; Kishimoto I
Diabet Med; 2016 Dec; 33(12):1737-1743. PubMed ID: 27150701
[TBL] [Abstract][Full Text] [Related]
15. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.
Gallagher EJ; Zelenko Z; Tobin-Hess A; Werner U; Tennagels N; LeRoith D
Diabetologia; 2016 Sep; 59(9):2018-25. PubMed ID: 27241182
[TBL] [Abstract][Full Text] [Related]
16. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study.
Buchs AE; Silverman BG
Metabolism; 2011 Oct; 60(10):1379-85. PubMed ID: 21696791
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine and risk of cancer: a meta-analysis.
Du X; Zhang R; Xue Y; Li D; Cai J; Zhou S; Huang Z; Yu R; Liu Y
Int J Biol Markers; 2012 Oct; 27(3):e241-6. PubMed ID: 22865296
[TBL] [Abstract][Full Text] [Related]
18. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
19. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
[TBL] [Abstract][Full Text] [Related]
20. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]